Dr. Gai is the founding partner of Global Assets Investment, LLC. Previously she was a Vice President of the Direct Investment Group of Merrill Lynch in New York where she was a founding team member of the companys China direct investment initiative. She also worked at Tiger Management where she specialized in equity research in biotech and pharmaceutical industries, and private equity investment in US biotechnology companies.

Dr. Gai has over 20 years of experience in cross-cultural technological and business collaborations between China and other countries. Her experience in the field of venture capital and connections in investment and industrial circles in the US and China have made her successful in investing in life science companies and in advising corporate clients to identify cross-border technological and/or manufacturing partners.

Dr. Lipson is a partner in Global Assets Investment LLC, where he reviews and authorizes investment decisions and provides scientific expertise to the company and its clients. He has provided consulting services to two biotechnology companies working in the area of therapeutic antibody discovery, and a venture capital company focused on investments in China.

Dr. Lipson has more than 15 years of experience in biotechnology and multinational pharmaceutical companies, including 3M Pharmaceuticals, Pharmacia, SUGEN and CIBA-Geigy (now Novartis), He has served in a variety of scientific and business leadership positions, and worked in multiple therapeutic areas, including oncology, cardiovascular, inflammation, metabolic and infectious diseases, which are all represented in his more than 75 publications in peer-reviewed journals, patent applications, review articles and book chapters.

Prior to his industrial experience, Dr. Lipson served on the faculty of the department of Pathology at Temple University Medical School. Dr. Lipson earned two simultaneous BS degrees in Biology and Chemistry from the University of Toledo, and a Ph.D. in Chemistry from Case Western Reserve University. His postdoctoral studies at Sloan-Kettering Institute and Temple University Medical School provided additional training in biochemistry, pharmacology, cell biology and molecular biology.